The TAILOR-PCI study is a multicenter clinical trial initiated by Mayo Clinic that seeks to discover if genetic testing can determine in advance the best anti-platelet therapy for patients undergoing coronary stent implantation.

TAILOR-PCI stands for Tailored Antiplatelet Initiation to Lessen Outcomes Due to Decreased Clopidogrel Response after Percutaneous Coronary Intervention (NCT01742117). The Center for Individualized Medicine at Mayo Clinic sponsors the TAILOR-PCI study.

The principal investigators for the TAILOR-PCI study are Naveen L. Pereira, M.D., a consultant in the Division of Cardiovascular Diseases at Mayo Clinic in Rochester, Minnesota, and Michael E. Farkouh, M.D., of the University of Toronto.

The Cardiovascular Research Center at Mayo Clinic is focused on discovering the underlying causes of cardiovascular disease and using these findings to propose new methods of treatment. This research is helping people who have percutaneous coronary intervention (PCI) with coronary stent implantation find the best anti-platelet therapy to enable the best results.

About the TAILOR-PCI study

Typically, people who undergo percutaneous coronary intervention are given clopidogrel (Plavix), an anti-platelet medication that prevents blood clots from forming.

Studies suggest that people who have a CYP2C19 liver enzyme abnormality may have a reduced ability to metabolize clopidogrel and therefore may experience blood clotting. Tests are available to determine whether someone has this genetic liver enzyme abnormality.

Ticagrelor (Brilinta) is a newer anti-platelet drug that is not dependent on the CYP2C19 liver enzyme. For people who are unable to metabolize clopidogrel, alternative drugs such as ticagrelor are recommended for an anti-platelet agent after percutaneous coronary intervention.

The purpose of the TAILOR-PCI study is to determine if individualized genetic testing can identify the best anti-platelet therapy for people who undergo a coronary stent placement and don't metabolize clopidogrel well.

Study eligibility

To be eligible for the TAILOR-PCI study, participants must meet certain criteria. They must:

  • Be age 18 or older
  • Have acute coronary syndrome or stable coronary artery disease
  • Be eligible for percutaneous coronary intervention
  • Be willing and able to provide informed written consent

More information

To learn more, watch a video in which Dr. Pereira discusses the TAILOR-PCI study, clinical trials and future implications of his research findings.

Dr. Pereira discusses the TAILOR-PCI study at Mayo Clinic

Get more information about the TAILOR-PCI study:


The TAILOR-PCI study is a multicenter international clinical trial initiated by Mayo Clinic in Rochester, Minnesota. Study centers are located in the United States, Canada, Korea and Mexico.

Contact information

For more information about the TAILOR-PCI study at Mayo Clinic, email the research team. Contact your doctor for study locations outside of Mayo Clinic.